Tumor response by PET-CT assessment
Tumor
LUNG METASTASIS, DISEASE, METASTASIS, TUMOR
Of the 8 evaluable patients, five were determined to have stable or decreased SUVmax values after 4 weeks of naltrexone (Fig. 
Tumor response by SUVmax after 4 and 8 weeks of therapy. Each individual patient is represented by a separate color. If one metastatic site decreased at week 4, the patient was considered to have stable disease. One patient was deemed to have progression (black) due to development of new sites at week 4Since patients had multiple sites of metastasis, each individual organ site was measured. The patient who had a partial response had a decrease in SUVmax of > 50% at one site of metastasis, however the rest of the metastatic sites had a decrease in SUVmax of < 50%.Among the 8 patients, 3 patients had lung metastasis. There was an overall decrease in SUVmax in the lung metastasis compared to other sites of metastasis in the 3 patients. Mean percentage decrease in SUVmax for lung metastasis among the three patients was 56%.